Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $42.6 million.

  • Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1100.97% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 1100.97%. This contributed to the annual value of $37.6 million for FY2024, which is 2797.94% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $42.6 million for Q3 2025, which was up 1100.97% from $42.4 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $42.6 million during Q3 2025, and registered a low of $20.6 million during Q4 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $26.8 million in 2023 and averaged $30.0 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 72851.53% in 2021, then tumbled by 510.59% in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $20.6 million in 2021, then rose by 19.78% to $24.6 million in 2022, then increased by 19.35% to $29.4 million in 2023, then grew by 27.98% to $37.6 million in 2024, then rose by 13.3% to $42.6 million in 2025.
  • Its last three reported values are $42.6 million in Q3 2025, $42.4 million for Q2 2025, and $39.3 million during Q1 2025.